Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenylmethanesulfonamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 12/20 | 0.95 |
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.50 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.50 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 7/20 | 0.95 |
| ▸ | CA9 | Q16790 | 4/20 | 0.95 |
| ▸ | CA5A | P35218 | 2/20 | 0.95 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.56 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | ELANE | P08246 | 1/20 | 0.56 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylmethanesulfonamide SCHEMBL7371 | 0.97 | CA2 (1.00) | CA2CA1CA9CA5APRSS1 | |
| Phenylmethanesulfonamide SCHEMBL3638470 | 0.95 | CA2 (0.95) | CA2CA1CA9CA5APRSS1 | |
| Phenylmethanesulfonamide SCHEMBL9006012 | 0.95 | CA2 (0.95) | CA2CA1CA9CA5APRSS1 | |
| Phenylmethanesulfonamide SCHEMBL4059166 | 0.95 | CA2 (0.95) | CA2CA1CA9CA5APRSS1 | |
| Phenylmethanesulfonamide SCHEMBL9400757 | 0.95 | CA2 (0.95) | CA2CA1CA9CA5APRSS1 | |
| Phenylmethanesulfonamide SCHEMBL31442719 | 0.95 | CA2 (0.95) | CA2CA1CA9CA5APRSS1 | |
| Phenylmethanesulfonamide SCHEMBL1546211 | 0.93 | CA2 (0.91) | CA2CA1CA9CA5APRSS1 | |
| Phenylmethanesulfonamide SCHEMBL9492234 | 0.91 | CA2 (0.86) | CA2CA1CA9CA5APRSS1 | |
| Phenylmethanesulfonamide SCHEMBL27420176 | 0.91 | CA2 (0.86) | CA2CA1CA9CA5APRSS1 | |
| Phenylmethanesulfonamide SCHEMBL28388564 | 0.89 | CA2 (0.83) | CA2CA1CA9CA5APRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111621484-A | Modified hot start enzyme and preparation method thereof | 济南国益生物科技有限公司 | 2020-09-04 | — | — | CN | claimed |
| US-20220089521-A1 | ETHYLENEDIAMINE COMPOUND AND USE THEREOF | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2022-03-24 | — | — | US | disclosed |
| EP-3849664-A1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| CN-112739420-A | Phenoxy-pyridyl-pyrimidine compounds and methods of use | 基因泰克公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-111621484-A | Modified hot start enzyme and preparation method thereof | 济南国益生物科技有限公司 | 2020-09-04 | — | — | CN | disclosed |
| WO-2020056089-A1 | PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2020-03-19 | — | — | WO | disclosed |
| CN-104220058-A | Serine racemase inhibitor | NAT UNIV CORP UNIV TOYAMA | 2014-12-17 | — | — | CN | disclosed |
| EP-2124913-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| CN-1832922-A | Sulfonyl-substituted N- (biarylmethyl) aminocyclopropanecarboxamides | MERCK & CO INC (US) | 2006-09-13 | — | — | CN | disclosed |
| CN-1653042-A | Aminoalcohol derivatives as beta-3 adrenergic receptor agonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-10 | — | — | CN | disclosed |
| CN-1303374-A | Substituted indolinones, process for their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA (DE) | 2001-07-11 | — | — | CN | disclosed |
| CN-1112117-A | Imidazole-containing inhibitors of farnesyl protein transferase | BRISTOL MYERS SQUIBB CO (US) | 1995-11-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089521-A1 | ETHYLENEDIAMINE COMPOUND AND USE THEREOF | UROD, FURIN, TMPRSS15 | CA2 3511/4885MMP1 2526/4885MMP8 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.